Why Surgical Menopause Causes More Severe Vaginal and Urinary Symptoms (GSM)
6 minute read
Summary
Surgical menopause occurs when both ovaries are removed during a medical procedure. Rather than the fluctuating, progressive hormonal changes that occur during natural menopause, this causes a rapid decline in estrogen and triggers an abrupt transition to menopause.
Because the transition is immediate, many women notice vaginal and urinary symptoms more rapidly and intensely than women who experience menopause gradually. New research suggests that surgical menopause may produce a distinct, more severe pattern of genitourinary symptoms, highlighting the importance of recognizing and treating these changes early.
Why Surgical Menopause Is Different
Surgical menopause occurs after a bilateral oophorectomy, which is removal of both ovaries. This can occur with or without a hysterectomy, which is the surgical removal of the uterus.
During natural menopause, estrogen production declines gradually over several years, giving tissues time to adapt to changing hormone levels. After bilateral oophorectomy, estrogen production plummets, leaving estrogen-sensitive tissues without a natural transition period.
The vagina, vulva, bladder, urethra, and pelvic floor contain abundant estrogen receptors and are responsive to changing estrogen levels throughout a woman’s life. The sudden loss of estrogen after surgical menopause affects tissue thickness, blood flow, collagen production, lubrication, elasticity, and the acidic vaginal environment that supports normal tissue health.
Understanding Genitourinary Syndrome of Menopause (GSM)
Genitourinary Syndrome of Menopause (GSM) is the medical term used to describe the collection of vaginal, vulvar, urinary, and sexual symptoms caused by declining estrogen during perimenopause as well as both surgical and non-surgical menopause. These symptoms were previously called "vaginal atrophy," but the term has since been updated to account for the multiple pelvic tissues affected during this time, and not just the vagina.
Symptoms of GSM include vaginal dryness, burning, irritation, itching, decreased lubrication, pain with intercourse, recurrent urinary tract infections, urinary discomfort, and urinary urgency and frequency. Unlike hot flashes, which can improve over time for some women, GSM is generally considered to be progressive. Without targeted treatments, these tissues continue to change after hormone levels decline.
Fortunately, when women report these symptoms, we have treatment options that can not only reduce symptoms, but also improve and restore the tissue. For example, low-dose vaginal estrogen is an ideal treatment for GSM.
Most women notice an improvement in their symptoms within a month and optimal tissue improvement at 12 weeks.
June 2026 Study: Severe Surgical GSM
Clinicians didn’t recognize until recently that GSM often developed more quickly after surgical menopause. A June 2026 study published in Menopause compared more than 400 postmenopausal women who experienced either natural menopause or surgical menopause.
The data revealed that surgical menopause triggers what researchers called a distinct, aggressive pattern characterized by a rapid loss of vaginal elasticity, tissue thinning, and altered vaginal pH. Women in the surgical group experienced increases in the frequency and intensity of vaginal burning and deep tissue pain with intercourse compared to their natural-menopause peers.
In the wake of the findings, Dr. Stephanie Faubion, the Director of Mayo Clinic Center for Women's Health and the Medical Director of The Menopause Society, has noted that waiting for symptoms to become more severe before prescribing localized treatment can cause unnecessary tissue damage. The Menopause Society now emphasizes that clinicians should recognize GSM early after surgical menopause.
Why GSM Affects Both Vaginal and Urinary Health
Like the vagina, the bladder, urethra, and lower urinary tract also contain estrogen receptors. Estrogen here also helps maintain tissue integrity, collagen, blood flow, and the balance of protective bacteria. As estrogen declines, these tissues may also become thinner, less elastic, and more susceptible to irritation or small areas of injury.
Estrogen also helps maintain the acidic vaginal environment that supports healthy bacteria. As estrogen levels decline, vaginal pH rises and the balance of protective bacteria changes. Together, these changes may increase the likelihood of recurrent urinary tract infections and bacterial vaginosis in some women.
Tissues in this area can become thin and fragile and lubrication can decrease causing micro-tears to occur during sexual activity, leading to pain, post-coital burning, and subsequent pelvic floor hypertonicity (muscle guarding). Physical pain often has other impacts, including sexual anxiety, loss of intimacy and strain on relationships.
Treatment After Surgical Menopause
Genitourinary Syndrome of Menopause (GSM) is treatable. Early recognition is important and may help preserve tissue health and reduce symptom progression.
Treatment depends on specific symptoms and their severity, whether systemic hormone therapy is appropriate, and a patient’s medical and cancer history. Low-dose vaginal estrogen delivers estrogen directly to vaginal tissues with minimal systemic absorption and is considered one of the most effective treatments for GSM. Systemic hormone replacement therapy (HRT) may improve some GSM symptoms but does not always fully address localized vaginal and urinary tissue changes. Some women benefit from using both HRT and vaginal estrogen.
Estradiol Vaginal Cream
$119.97
Nonhormonal vaginal moisturizers and lubricants may improve comfort, particularly for women who cannot or choose not to use estrogen.
The best treatment plan is individualized based on symptoms, preferences, and medical history.
Questions to Ask Your Care Team
If surgical menopause is planned, ask your doctor whether vaginal and urinary symptoms should be anticipated and how they will be monitored after surgery. Inquire whether localized vaginal estrogen or another treatment would be appropriate if symptoms develop. Discuss when treatment can safely begin after surgery and what symptoms should prompt earlier evaluation. Women who have already undergone surgical menopause can also discuss new vaginal or urinary symptoms with their clinician, even if surgery occurred months or years earlier. Localized treatments can be started at any time if symptoms are bothersome.
There is no need to suffer. If you are having new urinary symptoms, painful intercourse, vaginal discomfort, bleeding, or recurrent urinary tract infections, ask your provider about your options. These symptoms are treatable and not something you have to endure. The board-certified, menopause-trained doctors at Alloy can help determine whether symptoms are related to GSM and develop an individualized treatment plan.
Frequently Asked Questions
What is surgical menopause and how does it differ from natural menopause?
Surgical menopause occurs following a bilateral oophorectomy, which is the surgical removal of both ovaries, performed with or without a hysterectomy. During natural menopause, estrogen production declines gradually over several years, allowing pelvic tissues time to adapt. In contrast, surgical menopause causes estrogen levels to plummet suddenly, leaving estrogen-sensitive tissues without a natural transition period.
What is Genitourinary Syndrome of Menopause (GSM)?
Genitourinary Syndrome of Menopause is the medical term describing the collection of vaginal, vulvar, urinary, and sexual symptoms caused by declining estrogen during perimenopause and both surgical and non-surgical menopause. The term replaced vaginal atrophy to reflect that multiple pelvic tissues are affected. Symptoms include dryness, burning, irritation, itching, decreased lubrication, pain with intercourse, urinary urgency, frequency, discomfort, and recurrent urinary tract infections. Unlike hot flashes, GSM is considered progressive and continues to advance without targeted treatment.
What did the June 2026 study reveal about surgical GSM?
The June 2026 study published in Menopause compared more than 400 postmenopausal women and revealed that surgical menopause triggers a distinct, aggressive pattern. This pattern is characterized by a rapid loss of vaginal elasticity, tissue thinning, altered vaginal pH, and increased frequency and intensity of vaginal burning and deep tissue pain. In response, Dr. Stephanie Faubion issued an advisory emphasizing that waiting for symptoms to worsen before prescribing localized treatment can cause unnecessary tissue damage that becomes harder to reverse later.
References
Özmen S, Balcı MF, Atay AO, Özdoğar ÖN, Onal Erdemir D. Genitourinary syndrome of menopause in surgical versus natural menopause: standardized clinical scoring. Menopause. 2026. (published online June 9, 2026). doi:10.1097/GME.0000000000002833.
Anjana C, Resmy CR, Ismail J. Onset and progression of urogenital symptoms after surgical menopause: a prospective cohort study. J Clin Diagn Res. 2024. doi:10.7860/JCDR/2024/67141.19076
The Menopause Society. Surgical menopause causes more severe genitourinary syndrome of menopause phenotype [press release]. June 10, 2026. Accessed July 16, 2026. Surgical Menopause Causes More Severe Genitourinary Syndrome of Menopause Phenotype
Portman DJ, Gass MLS; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society. Menopause. 2014;21(10):1063-1068. doi:10.1097/GME.0000000000000329
The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976-992. doi:10.1097/GME.0000000000001609
Phillips N, Bachmann G. The genitourinary syndrome of menopause. Menopause. 2021;28(5):579-588. doi:10.1097/GME.0000000000001728
Faubion SS, Sood R, Kapoor E. Genitourinary syndrome of menopause: management strategies for the clinician. Mayo Clin Proc. 2017;92(12):1842-1849. 10.1016/j.mayocp.2017.08.019
Tsuboi I, Inoue S, Hirayama T, et al. Gut, vaginal, and urinary microbiome alterations in women with genitourinary syndrome of menopause: a systematic review. 2026. Maturitas. 2026;Jun 23:211:109031. doi: 10.1016/j.maturitas.2026.109031.
Biehl C, Plotsker O, Mirkin S. A systematic review of the efficacy and safety of vaginal estrogen products for the treatment of genitourinary syndrome of menopause. Menopause. 2019;26(4):431-453. doi: 10.1097/GME.0000000000001221.
The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. doi:10.1097/GME.0000000000002028
Subscribe
Go ahead, you deserve to
feel fantastic
By subscribing you agree to our Terms of Service & Privacy Policy.